Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Brooks Laboratories

BROOKS
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Brooks Laboratories Share price and Fundamental Analysis

View All Details
View All Details
Brooks Laboratories Ltd is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency.
Company Incorporation2002
ChairmanNA
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
435.97
PE Ratio
0
Industry P/E
34.61
PEG Ratio
0
ROE
-10.16%
ROCE
-8.25%
ROA
-8.05%
Total Debt (Cr)
7.58
Debt to Equity
0.08
Dividend Yield
0%
EPS
0
Book Value & P/B
39.06 x 3.79
Face Value
10
Outstanding Shares(Cr)
2.95
Current Ratio
2.04
EV to Sales
5.36

Stock Returns

1 Week+11.37%
1 Month+10.16%
6 Months+8.62%
1 Year+99.43%
3 Years+70.7%
5 Years+353.02%

CAGR

1 Year CAGR

Revenue Growth

+25.76%

Net Profit Growth

-36.91%

Operating Profit Growth

-114.31%

Dividend Growth

N/A

Stock Returns CAGR

+95.07%
no_data

No Stocks

Smart Score

2.6
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 52.62%

FIIs : 0.05%

DIIs : 10.38%

Public : 36.95%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
FII Shareholding Increased by 0.05% to 0.05% in March 2025 Qtr
DII Shareholding Increased by 0.48% to 10.38% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Brooks Laboratories Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Brooks Laboratories Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Brooks Laboratories Ltd is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency.

The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.

The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

The company's major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.

Brooks Laboratories Ltd was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.

In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (R&D) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.

In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal & Rajesh Mahajan.

In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS & IAF.

In August 2011, Brooks Laboratories raised Rs. 63 crore from the public through IPO. The shares of the company got listed on the stock exchanges with effect from 5 September 2011.

During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity.

On 7 March 2017, Brooks Laboratories' world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.

The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. During the year ended 31 March 2018, the company operated the Baddi plant at 90% capacity except for 3 months from June to August due to upgradation of injectable facility in Baddi.

The company commenced production in August 2017 in new renovated building at Baddi plant with almost double the capacity of previous line.

Brooks Laboratories Share Price

Brooks Laboratories share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Brooks Laboratories Market Cap

Market capitalization of Brooks Laboratories indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Brooks Laboratories is valued compared to its competitors.

Brooks Laboratories PE Ratio

Brooks Laboratories PE ratio helps investors understand what is the market value of each stock compared to Brooks Laboratories 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Brooks Laboratories PEG Ratio

The PEG ratio of Brooks Laboratories evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Brooks Laboratories ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Brooks Laboratories generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Brooks Laboratories ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Brooks Laboratories in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Brooks Laboratories Total Debt

Total debt of Brooks Laboratories shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Brooks Laboratories Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Brooks Laboratories compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Brooks Laboratories CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Brooks Laboratories over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Brooks Laboratories Technical Analysis

Technical analysis of Brooks Laboratories helps investors get an insight into when they can enter or exit the stock. Key components of Brooks Laboratories Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Brooks Laboratories shares often struggle to rise above due to selling pressure.

Brooks Laboratories Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Brooks Laboratories ’s financial health and profitability.

Brooks Laboratories Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Brooks Laboratories Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Brooks Laboratories Financials

The financials of Brooks Laboratories provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Brooks Laboratories Profit and Loss Statements

The profit and loss statement of Brooks Laboratories highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Brooks Laboratories .

Brooks Laboratories Balance Sheet

The balance sheet presents a snapshot of Brooks Laboratories ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Brooks Laboratories Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App